Evaxion Biotech A/S (EVAX) News Today $1.65 +0.06 (+3.77%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$1.64 -0.01 (-0.91%) As of 04/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Evaxion Biotech: Evaxion to present at World Vaccine CongressApril 10, 2025 | finanznachrichten.deEvaxion to present at World Vaccine CongressApril 10, 2025 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call TranscriptApril 4, 2025 | msn.comEarnings call transcript: Evaxion Biotech Q4 2024 sees improved financialsApril 3, 2025 | uk.investing.comEvaxion Biotech’s Optimistic Earnings Call HighlightsApril 2, 2025 | tipranks.comEvaxion Biotech reports Q4 EPS (7c) vs (17c) last yearApril 2, 2025 | markets.businessinsider.comQ4 2024 Evaxion Biotech A/S Earnings CallApril 2, 2025 | finance.yahoo.comEvaxion Biotech Reports 2024 Financial Results and Strategic ProgressApril 2, 2025 | tipranks.comQ4 2024 Evaxion Biotech A/S Earnings Call TranscriptApril 2, 2025 | gurufocus.comEvaxion Biotech A/S (EVAX) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comEvaxion announces business update and full year 2024 financial resultsApril 1, 2025 | markets.businessinsider.comA Glimpse of Evaxion Biotech's Earnings PotentialMarch 31, 2025 | benzinga.comAgillic appoints new CFO Jack SørensenMarch 31, 2025 | finance.yahoo.comEvaxion to announce business update and full year 2024 financial results on April 1, 2025March 27, 2025 | globenewswire.comEvaxion Biotech: Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual MeetingMarch 25, 2025 | finanznachrichten.deEvaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual MeetingMarch 25, 2025 | globenewswire.comEvaxion Biotech files $50M ordinary shares offeringMarch 14, 2025 | markets.businessinsider.comEvaxion to present at numerous upcoming conferencesMarch 4, 2025 | markets.businessinsider.comEVAX Adds to Trial Due to Excellent ResultsFebruary 27, 2025 | msn.comEvaxion Biotech: Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data packageFebruary 25, 2025 | finanznachrichten.deEvaxion Biotech extends Phase 2 trial with EVX-01 to enhance clinical dataFebruary 25, 2025 | markets.businessinsider.comEvaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data packageFebruary 25, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Harmony Biosciences Holdings (HRMY)February 20, 2025 | markets.businessinsider.comEvaxion Biotech: Nasdaq confirms Evaxion is fully compliant, withdraws delisting determinationFebruary 14, 2025 | finanznachrichten.deEvaxion secures Nasdaq listing with equity boostFebruary 14, 2025 | msn.comEvaxion Biotech re-established compliance with NasdaqFebruary 14, 2025 | markets.businessinsider.comEvaxion Biotech (EVAX) Receives a Buy from Lake StreetFebruary 4, 2025 | markets.businessinsider.comEvaxion Biotech price target lowered to $6 from $35 at Lake StreetFebruary 4, 2025 | markets.businessinsider.comH.C. Wainwright maintains Evaxion stock Buy rating, $14 targetFebruary 4, 2025 | msn.comEvaxion Biotech Closes $10.8 Million Public Offering to Boost Vaccine DevelopmentJanuary 31, 2025 | tipranks.comEvaxion announces closing of $10.8 million public offeringJanuary 31, 2025 | globenewswire.comEvaxion Biotech stock slides after pricing $10.8M securities offeringJanuary 30, 2025 | msn.comEvaxion Biotech stock slides after pricing $10.8M securities offeringJanuary 30, 2025 | msn.comEvaxion Biotech prices 3.997M ADSs at $2.71 in public oferingJanuary 30, 2025 | markets.businessinsider.comEvaxion Biotech prices 3.997M ADSs at $2.71 in public oferingJanuary 30, 2025 | markets.businessinsider.comEvaxion Biotech stock hits 52-week low at $2.38 amid market challengesJanuary 30, 2025 | msn.comEvaxion Biotech stock hits 52-week low at $2.38 amid market challengesJanuary 30, 2025 | msn.comEvaxion announces pricing of $10.8 million public offeringJanuary 30, 2025 | globenewswire.comEvaxion Biotech granted 180-day compliance extension by NasdaqJanuary 28, 2025 | markets.businessinsider.comEvaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirementJanuary 28, 2025 | globenewswire.comEvaxion Biotech (NASDAQ:EVAX) Stock Quotes, Forecast and News SummaryJanuary 25, 2025 | benzinga.comEvaxion Biotech stock hits 52-week low at $3.06 amid sharp declineJanuary 17, 2025 | msn.comEvaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01January 16, 2025 | finanznachrichten.deEvaxion Biotech completes dosing in phase 2 trial with EVX-01January 16, 2025 | markets.businessinsider.comEvaxion concludes subject dosing in Phase II trial of melanoma vaccineJanuary 16, 2025 | finance.yahoo.comEvaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-01January 16, 2025 | markets.businessinsider.comEvaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01January 15, 2025 | markets.businessinsider.comEvaxion announces completion of ADS ratio changeJanuary 14, 2025 | globenewswire.comEvaxion Biotech trading halted, news pendingJanuary 14, 2025 | markets.businessinsider.comEvaxion announces extension to January 14 of plan to implement ADS ratio changeJanuary 10, 2025 | markets.businessinsider.com Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Media Mentions By Week EVAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼1.430.94▲Average Medical News Sentiment EVAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼22▲EVAX Articles Average Week Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biofrontera News Today Addex Therapeutics News Today Mainz Biomed News Today TransCode Therapeutics News Today Omega Therapeutics News Today Indaptus Therapeutics News Today AIM ImmunoTech News Today Apollomics News Today Silexion Therapeutics News Today Aytu BioPharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVAX) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
